SSRIs
High-yield Verified · Oct 2026Prototype: sertraline
SSRIs are a class of medications used for major depressive disorder.
Selective serotonin reuptake inhibitors. No single stem — learn them by mechanism (fluoxetine, sertraline, escitalopram, paroxetine).
How it works in the body
The system involved, what goes wrong, and how the drug and body interact.
01 The serotonin hypothesis and the synapse
The leading — though admittedly incomplete — model of depression is the monoamine hypothesis: depressive symptoms are linked to too little signaling by monoamine neurotransmitters, especially serotonin (5-HT), in the brain circuits that regulate mood, sleep, appetite, and anxiety. SSRIs are built directly on this idea: raise serotonin in the synapse, relieve the symptoms.
Here is the machinery. When a serotonin neuron fires, it releases 5-HT into the synaptic cleft, where it activates receptors on the next neuron. The signal is then switched off by the serotonin transporter (SERT), a pump on the sending neuron that vacuums serotonin back up for reuse (reuptake). SSRIs block SERT, so serotonin lingers in the cleft and keeps stimulating the receiving neuron. They are "selective" because they leave the norepinephrine and dopamine pumps largely alone.
02 Why relief is delayed — the pill works on day one, the patient feels it in weeks
The single most important teaching point about SSRIs is the delayed onset. The reuptake block begins with the first doses, yet the antidepressant effect takes 4 to 6 weeks (sometimes longer). If the reuptake block starts with the first doses, why the lag?
The best-supported explanation is neuroadaptation. Serotonin also acts on inhibitory 5-HT1A autoreceptors on the serotonin neuron itself, which hold back the neuron’s own firing — blunting the net effect at first. These autoreceptors desensitize over weeks, on the same time course as the clinical response, and slower downstream changes (including raised BDNF and neuroplasticity) support the lift in mood. The clinical consequence is critical: a patient must be told to keep taking a drug that is not working yet, and the first months and any dose change carry a specific danger — antidepressants increased suicidal thoughts and behaviors in children and young adults, so every patient is watched for clinical worsening.
03 Why the side effects follow — serotonin is everywhere
Serotonin is not a brain-only molecule. Most of the body’s serotonin lives in the gut, and it is stored in platelets — so raising serotonergic tone has predictable effects far from the mood circuits. In the GI tract the extra serotonin causes early nausea and diarrhea (often transient). Effects on serotonergic sexual pathways cause sexual dysfunction. In platelets, which use serotonin in clumping, SSRIs raise bleeding risk — additive with NSAIDs, antiplatelets, and anticoagulants.
Two mirror-image dangers bracket the therapeutic window. Too much serotonergic activity — usually when an SSRI is combined with another serotonergic drug — causes serotonin syndrome, a potentially fatal storm of altered mental status, autonomic instability, and neuromuscular hyperactivity (the classic clue is clonus and hyperreflexia, worse in the legs). And the sudden loss of serotonin when a drug is stopped abruptly — after the brain has adapted to high levels — causes a discontinuation syndrome (dizziness, flu-like feelings, and the characteristic electric-shock "brain zaps").
Drug names
Indications
- Major depressive disorder (first-line)
- Anxiety-spectrum disorders — GAD, panic disorder, OCD, social anxiety
- PTSD; plus agent-specific uses (bulimia, PMDD)
Mechanism of action
Selectively inhibit the presynaptic serotonin transporter (SERT), blocking reuptake of serotonin from the synaptic cleft and increasing serotonin available to stimulate postsynaptic 5-HT receptors. With sustained use, down-regulation of inhibitory autoreceptors and downstream neuroadaptation produce the antidepressant and anxiolytic effect — accounting for the delayed clinical onset.
Therapeutic effects — what you'll see working
Set expectations up front: the reuptake block starts with the first doses but the felt benefit takes weeks, and it builds gradually. Track mood, sleep, appetite, and anxiety over time with validated scales — and watch the early months and any dose change closely for clinical worsening or emerging suicidal thoughts.
- Improved mood (over weeks)
- Sustained serotonergic signaling plus neuroadaptation gradually lifts depressed mood, hopelessness, and anhedonia. Judge with a validated scale (e.g., PHQ-9); expect a meaningful response by 4–6 weeks, not days.
- Reduced anxiety, panic & obsessions
- Serotonergic modulation of limbic circuits eases GAD, panic, and OCD symptoms — though anxiety may transiently worsen ("jitteriness") early in treatment before it improves, which is worth warning patients about.
- Restored sleep, appetite & energy
- As depression lifts, sleep, appetite, and energy improve along with mood. Early in treatment, a very depressed patient may regain the energy to act on suicidal thoughts they previously lacked the energy to act on — one reason the early-treatment months need close suicidality monitoring.
Adverse effects
The side effects trace back to serotonin’s wide distribution (gut, platelets, sexual pathways) and to the two extremes of the window — too much serotonin (serotonin syndrome) and its abrupt loss (discontinuation).
Interactions
Contraindications
The defining contraindication is combining an SSRI with anything else that raises serotonin — above all a monoamine oxidase inhibitor.
Nursing considerations
The RN-specific layer — each action paired with the reason it matters.
Common questions
What are SSRIs used for?
How do SSRIs work?
What are the serious side effects of SSRIs?
Conditions treated
"Selective serotonin reuptake inhibitors are another alternative if the TCAs are not tolerated."
First-line across this whole page, and the sources give the mechanism that justifies it. In generalized anxiety: "reduced serotonergic activity and increased noradrenergic activity may contribute to the development of generalized anxiety disorder. Consequently, SSRIs and SNRIs are first-line medications for treatment." In panic disorder: "SSRIs are considered the first-line treatment option," and they are "recommended over monoamine oxidase inhibitors and tricyclic antidepressants." In PTSD the naming is a guideline recommendation, not a labelling accident: VA/DoD 2023 recommends paroxetine, sertraline or venlafaxine (Rec 15, STRONG for) — two SSRIs and one SNRI, named together at the same strength. Sertraline and paroxetine are also the FDA-cleared agents, and the carrier adds that "there is no strong evidence to differentiate the effectiveness of specific SSRIs and SNRIs." Set the expectation honestly on both effect size and time. Response rates in generalized anxiety are 30% to 50%, with escitalopram, duloxetine, venlafaxine extended-release and paroxetine named as first-line agents. On timing, what is sourced here is "gradual dose titration and continuation for at least 4 weeks to assess effectiveness," then "once symptoms are controlled, treatment should continue for at least 12 months, followed by gradual tapering" — and the nursing version, that antidepressants "can take several weeks to reach their optimal effectiveness, so it is important to teach clients to give the medication appropriate time before reaching a conclusion about its effectiveness." Combination beats either alone in children: 81% of children with anxiety disorders who received combined sertraline and cognitive behavioral therapy responded. Do not stop abruptly — antidepressants "should be tapered off slowly to safely decrease the dose because stopping them abruptly can cause withdrawal symptoms." Monitor the metabolic consequences, because "adverse effects, including weight gain, hyperlipidemia, and diabetes, may occur with some medications." Two supplement interactions belong to the disorder-side conversation: kava may cause liver injury, while St John’s wort and 5-hydroxytryptophan may interact with SSRIs and precipitate serotonin syndrome. The Depression page owns the antidepressant boxed warning, the antidepressant onset window and serotonin-syndrome recognition.
Mostly a warning, and the warning is the teaching. Per the guidelines as reported by StatPearls, "antidepressant monotherapy is not recommended for bipolar I depression and should generally be avoided in patients with mixed features, rapid cycling, or previous antidepressant-induced switching," because antidepressant monotherapy "can precipitate mania, hypomania, or rapid cycling." What is permitted is combined use: "when antidepressants are used, they should typically be combined with a mood stabilizer or antipsychotic and closely monitored" — the nursing version is that an antidepressant may treat a bipolar depressive episode "in combination with a mood stabilizer and/or an antipsychotic to prevent precipitating a manic episode." In acute mania, antidepressants and other activating agents are discontinued when clinically appropriate. NIMH states antidepressants "are not used alone because they can trigger a manic episode or rapid cycling." Fluoxetine’s named bipolar role is the olanzapine-fluoxetine combination, which "remains an evidence-supported option but is often reserved because of metabolic adverse effects" — never an SSRI alone. The diagnostic corollary is worth more than the prescribing rule: mood switching or activation on an antidepressant is one of the features that should raise suspicion of bipolar disorder in a patient being treated for depression. The Depression page owns the monitoring instruction to report new increased activity and talking when an antidepressant is started or changed, and it owns the FDA antidepressant boxed warning.
First-line for MDD — chosen for safety, efficacy, and tolerability: minimal effect on dopamine, norepinephrine, histamine, and acetylcholine spares patients the anticholinergic, sedative, and cognitive burden of the older agents. Sertraline and escitalopram are commonly recommended first. In a population at suicide risk, a drug that is hard to die from in overdose is itself a safety intervention.
Fluoxetine is the only FDA-approved drug for bulimia nervosa. "Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), is FDA-approved for the treatment of bulimia nervosa (BN) and has demonstrated efficacy in reducing binge-purge behaviors," and StatPearls adds that "a higher dose (60 mg) is significantly better than a placebo in decreasing the frequency of binge and vomiting episodes." In anorexia, SSRIs are used with therapy for comorbid anxiety or depression once the patient is no longer acutely ill — they do not treat the anorexia itself.
Depression and irritability. EHDN (2019): "It is recommended to use a selective SSRI or a serotonin noradrenaline reuptake inhibitor (SNRI)" for depression, and "SSRIs are first lines for irritability (Grade C)." StatPearls cautions that "no convincing evidence of their use in Huntington disease has been documented." Fluoxetine and paroxetine are strong CYP2D6 inhibitors that limit the tetrabenazine dose (XENAZINE label).
First-line medication. "Selective serotonin reuptake inhibitors (SSRIs) are recommended as the first-line medications due to their proven efficacy, safety, and tolerability." "Higher dosages than those used for other anxiety disorders or major depressive disorder are typically prescribed" (StatPearls). Onset: NIMH says 8–12 weeks, while StatPearls notes meta-analyses showing "significant symptom improvement within the first 2 weeks." Fluvoxamine ER is labeled "for the treatment of obsessive compulsive disorder (OCD)." Maintenance "for at least 12 to 24 months postremission" (StatPearls).
Adjunct for specific symptoms only — no FDA-approved drug treats a personality disorder. "No medications are approved by the US Food and Drug Administration for the treatment of BPD" (StatPearls). NIMH: medication "is not a first-line treatment" but may help as an add-on for "co-occurring conditions such as mood swings or depression." StatPearls: serotonin reuptake inhibitors, mood stabilizers and antipsychotics "showed limited effectiveness for controlling transient symptoms of anxiety, sleep disturbance, depression, or agitation."
Pruritus — an initial option alongside antihistamines (StatPearls).
Antidepressants for PPD; sertraline in breastfeeding. NIMH: "Treatment for perinatal depression usually includes therapy, medication, or a combination of therapy and medication." "Antidepressants take time—usually 4−8 weeks—to work." LactMed: "Most authoritative reviewers consider sertraline a preferred antidepressants during breastfeeding" — infant levels are small, but "Rarely, preterm infants with impaired metabolic activity might accumulate the drug." FDA advice via NIMH: people under 25 may have more suicidal thoughts early in treatment; watch all ages closely in the first weeks. Zuranolone (Zurzuvae) — a separate drug, "a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of postpartum depression (PPD) in adults": once daily in the evening with fat-containing food for 14 days; boxed warning for driving impairment. Brexanolone "has been discontinued by the manufacturer."
See also
Potent pain control via µ-opioid receptor agonism. Watch for respiratory depression; reverse with naloxone.
Potentiate GABA for anxiety, seizures, and sedation. Additive CNS depression — deadly with opioids.
Stabilize neuronal firing to prevent seizures. Many are narrow-therapeutic-index — level monitoring and rash vigilance are essential.
A widely used fever/pain reliever with no anti-inflammatory or platelet effect — but hepatotoxic in overdose.
Dopamine-blocking drugs for psychosis. Watch EPS, NMS, metabolic effects — boxed warning in elderly dementia.
Lithium controls bipolar mania but has a tiny therapeutic window — levels are everything.
Sources
- Selective Serotonin Reuptake Inhibitors — MOA, delayed onset, adverse effects — StatPearls (NCBI)
- Serotonin Syndrome — clinical features & management — StatPearls (NCBI)
- Zoloft (sertraline) — boxed warning, contraindications, serotonin syndrome, hyponatremia, bleeding (FDA label) — FDA / DailyMed
- Prozac (fluoxetine) — FDA label — FDA / DailyMed
- Lexapro (escitalopram) — FDA label — FDA / DailyMed
- Celexa (citalopram) — QT, hyponatremia, discontinuation (FDA label) — FDA / DailyMed
- Paxil (paroxetine) — FDA label — FDA / DailyMed
- Physiology, Serotonin — StatPearls (NCBI)
- Paroxetine — discontinuation syndrome — StatPearls (NCBI)
- Citalopram — neurotrophic (BDNF) hypothesis — StatPearls (NCBI)
- Overcoming Resistance to SSRIs: 5-HT1A autoreceptors (Front Neurosci 2019) — Frontiers in Neuroscience (PMC, CC BY)
- Nursing: Mental Health and Community Concepts 2e, Ch. 6 Psychotropic Medications — Open RN — Open RN (NCBI Bookshelf, CC BY 4.0)
- WHO INN stem book 2018 — -oxetine / -traline — World Health Organization
- Fluoxetine — monitoring (PHQ-9) — StatPearls (NCBI)
- Nursing: Mental Health and Community Concepts 2e, 7.5 Applying the Nursing Process to Depressive Disorders — Open RN — Open RN (NCBI Bookshelf, CC BY 4.0)
Reviewed by Hae Suk Lee, RN
Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.